Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 09 2020 - 7:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
For the month of November 2020
Commission File Number: 001-37643
KITOV PHARMA LTD.
(Translation of registrant’s name
into English)
One Azrieli Center, Round Tower, Tel
Aviv 6701101, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the Registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the Registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On November 9, 2020, Kitov Pharma Ltd.
(the “Company” or the “Registrant”) issued a press release, “Kitov Expands Planned Phase 1/2 Clinical
Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted
with Bristol Myers Squibb”, which is attached hereto as Exhibit 99.1.
Exhibits
Incorporation
by Reference
This Form 6-K,
including all exhibits attached hereto, is hereby incorporated by reference into each
of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on December 12,
2016 (Registration file numbers 333-207117
and 333-211477),
the Registrant’s Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration
file number 333-211478), the Registrant’s Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration
file number 333-218538), the Registrant’s Registration Statement on Form
F-3, as amended, originally filed with the Securities and Exchange Commission on July
16, 2018 (Registration file number 333-226195), the Registrant’s Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration
file number 333-230584), the Registrant’s Registration Statement on Form
F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration
file number 333-233795), the Registrant’s Registration Statement on Form
F-3 filed with the Securities and Exchange Commission on December 2, 2019 (Registration
file number 333-235327), the Registrant’s Registration Statement on Form
F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration
file number 333- 238229), the Registrant’s Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on May 28, 2020 (Registration
file number 333-238481) and each of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange
Commission on July 10, 2020 (Registration file numbers 333-239807
and 333-233793),
to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports
subsequently filed or furnished.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
November 9, 2020
|
KITOV PHARMA LTD.
|
|
|
|
|
By:
|
/s/ Isaac Israel
|
|
|
Isaac Israel
|
|
|
Chief Executive Officer
|
2
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Sep 2023 to Sep 2024